Evidence map›Paper›PMID 33662023›Full record

ArticlePLoS pathogens2021

Protective porcine influenza virus-specific monoclonal antibodies recognize similar haemagglutinin epitopes as humans.

Barbara Holzer, Pramila Rijal, Adam McNee, Basudev Paudyal, Veronica Martini, Becky Clark, Tanuja Manjegowda, Francisco J Salguero, Emily Bessell, John C Schwartz and 13 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Molecular divergence and convergence of mammalian antibody responses to the influenza virus hemagglutinin stem.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 6 institutions in 2 countries.

Barbara HolzerThe Pirbright Institute, Pirbright, United Kingdom.
Pramila RijalCentre for Translational Immunology, Chinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-9214-9851
Adam McNeeThe Pirbright Institute, Pirbright, United Kingdom.ORCID 0000-0003-0591-308X
Basudev PaudyalThe Pirbright Institute, Pirbright, United Kingdom.ORCID 0000-0001-6068-019X
Veronica MartiniThe Pirbright Institute, Pirbright, United Kingdom.ORCID 0000-0002-6086-0358
Becky ClarkThe Pirbright Institute, Pirbright, United Kingdom.
Tanuja ManjegowdaThe Pirbright Institute, Pirbright, United Kingdom.ORCID 0000-0003-0226-4491
Francisco J SalgueroPublic Health England (PHE), Porton Down, Salisbury, United Kingdom.ORCID 0000-0002-5315-3882
Emily BessellThe Pirbright Institute, Pirbright, United Kingdom.
John C SchwartzThe Pirbright Institute, Pirbright, United Kingdom.ORCID 0000-0003-2057-1831
Katy MoffatThe Pirbright Institute, Pirbright, United Kingdom.ORCID 0000-0003-0120-7196
Miriam PedreraThe Pirbright Institute, Pirbright, United Kingdom.ORCID 0000-0003-4868-6630
Simon P GrahamThe Pirbright Institute, Pirbright, United Kingdom.ORCID 0000-0003-4852-405X
Alistair NobleThe Pirbright Institute, Pirbright, United Kingdom.ORCID 0000-0003-3936-1789
Marie Bonnet-Di PlacidoThe Pirbright Institute, Pirbright, United Kingdom.ORCID 0000-0002-8299-5595
Roberto M La RagioneDepartment of Pathology and Infectious Diseases, School of Veterinary Medicine, University of Surrey, Guildford, United Kingdom.
William MwangiThe Pirbright Institute, Pirbright, United Kingdom.
Peter BeverleyNational Heart and Lung Institute, St Mary's Campus, Imperial College London, United Kingdom.ORCID 0000-0003-0481-2180
John W McCauleyWorldwide Influenza Centre, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0002-4744-6347
Rodney S DanielsWorldwide Influenza Centre, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0003-2818-5089
John A HammondThe Pirbright Institute, Pirbright, United Kingdom.ORCID 0000-0002-2213-3248
Alain R TownsendCentre for Translational Immunology, Chinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-3702-0107
Elma TchilianThe Pirbright Institute, Pirbright, United Kingdom.ORCID 0000-0002-4869-5118
The Pirbright Institute · GBAcademy of Medical Sciences · GBThe Francis Crick Institute · GBImperial College London · GBPublic Health England · GBUniversity of Surrey · GB

Funding

Biotechnology and Biological Sciences Research Council BBS/E/I/00007031Biotechnology and Biological Sciences Research Council BBS/E/I/00007038Biotechnology and Biological Sciences Research Council BBS/E/I/00007039Cancer Research UK FC001030Medical Research Council FC001030Medical Research Council MR/P021336/1Wellcome Trust FC001030
6 · The paper itself

Abstract

Pigs are natural hosts for the same subtypes of influenza A viruses as humans and integrally involved in virus evolution with frequent interspecies transmissions in both directions. The emergence of the 2009 pandemic H1N1 virus illustrates the importance of pigs in evolution of zoonotic strains. Here we generated pig influenza-specific monoclonal antibodies (mAbs) from H1N1pdm09 infected pigs. The mAbs recognized the same two major immunodominant haemagglutinin (HA) epitopes targeted by humans, one of which is not recognized by post-infection ferret antisera that are commonly used to monitor virus evolution. Neutralizing activity of the pig mAbs was comparable to that of potent human anti-HA mAbs. Further, prophylactic administration of a selected porcine mAb to pigs abolished lung viral load and greatly reduced lung pathology but did not eliminate nasal shedding of virus after H1N1pdm09 challenge. Hence mAbs from pigs, which target HA can significantly reduce disease severity. These results, together with the comparable sizes of pigs and humans, indicate that the pig is a valuable model for understanding how best to apply mAbs as therapy in humans and for monitoring antigenic drift of influenza viruses in humans, thereby providing information highly relevant to making influenza vaccine recommendations.

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, ViralEpitopesHemagglutinin Glycoproteins, Influenza VirusHemagglutininsHumansInfluenza A virusInfluenza A Virus, H1N1 SubtypeInfluenza, HumanInfluenza VaccinesSwineAntibodies, MonoclonalAntibodies, ViralEpitopesHemagglutinin Glycoproteins, Influenza VirusHemagglutininsInfluenza Vaccines

Identifiers

PMID33662023
PMCPMC7932163
OpenAlexW3135779440

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.